{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:43:01Z","timestamp":1791286981484,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,4,3]],"date-time":"2008-04-03T00:00:00Z","timestamp":1207180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,4,3]],"date-time":"2008-04-03T00:00:00Z","timestamp":1207180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/leu.2008.74","type":"journal-article","created":{"date-parts":[[2008,4,3]],"date-time":"2008-04-03T10:02:36Z","timestamp":1207216956000},"page":"1191-1199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism"],"prefix":"10.1038","volume":"22","author":[{"given":"H","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Trachootham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Carew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R B","family":"Arlinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,4,3]]},"reference":[{"key":"BFleu200874_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164\u2013172.","journal-title":"N Engl J Med"},{"key":"BFleu200874_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172\u2013183.","journal-title":"Nat Rev Cancer"},{"key":"BFleu200874_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441\u2013453.","journal-title":"Nat Rev Cancer"},{"key":"BFleu200874_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031\u20131037.","journal-title":"N Engl J Med"},{"key":"BFleu200874_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645\u2013652.","journal-title":"N Engl J Med"},{"key":"BFleu200874_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876\u2013880.","journal-title":"Science"},{"key":"BFleu200874_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117\u2013125.","journal-title":"Cancer Cell"},{"key":"BFleu200874_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276\u2013283.","journal-title":"Blood"},{"key":"BFleu200874_CR9","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bbrc.2004.05.113","volume":"319","author":"M Yamamoto","year":"2004","unstructured":"Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O . The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR\/ABL fusion kinase. Biochem Biophys Res Commun 2004; 319: 1272\u20131275.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu200874_CR10","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531\u20132541.","journal-title":"N Engl J Med"},{"key":"BFleu200874_CR11","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207\u20133213.","journal-title":"Blood"},{"key":"BFleu200874_CR12","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332\u20132338.","journal-title":"Blood"},{"key":"BFleu200874_CR13","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1056\/NEJMe068073","volume":"354","author":"BJ Druker","year":"2006","unstructured":"Druker BJ . Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006; 354: 2594\u20132596.","journal-title":"N Engl J Med"},{"key":"BFleu200874_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrd2324","volume":"6","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J . Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6: 834\u2013848.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu200874_CR15","doi-asserted-by":"publisher","first-page":"24273","DOI":"10.1074\/jbc.M002094200","volume":"275","author":"M Sattler","year":"2000","unstructured":"Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275: 24273\u201324278.","journal-title":"J Biol Chem"},{"key":"BFleu200874_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2004-03-0849","volume":"105","author":"JH Kim","year":"2005","unstructured":"Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D et al. Activation of the PI3K\/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717\u20131723.","journal-title":"Blood"},{"key":"BFleu200874_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","volume":"108","author":"M Koptyra","year":"2006","unstructured":"Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. T BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319\u2013327.","journal-title":"Blood"},{"key":"BFleu200874_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ccr.2006.08.009","volume":"10","author":"D Trachootham","year":"2006","unstructured":"Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10: 241\u2013252.","journal-title":"Cancer Cell"},{"key":"BFleu200874_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1349-7006.2005.00038.x","volume":"96","author":"Q Zhang","year":"2005","unstructured":"Zhang Q, Tsukahara F, Maru Y . N-acetyl-cysteine enhances growth in BCR-ABL-transformed cells. Cancer Sci 2005; 96: 240\u2013244.","journal-title":"Cancer Sci"},{"key":"BFleu200874_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3324\/haematol.10955","volume":"92","author":"H Konig","year":"2007","unstructured":"Konig H, Hartel N, Schultheis B, Schatz M, Lorentz C, Melo JV et al. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. Haematologica 2007; 92: 838\u2013841.","journal-title":"Haematologica"},{"key":"BFleu200874_CR21","first-page":"3603","volume":"53","author":"M Beran","year":"1993","unstructured":"Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993; 53: 3603\u20133610.","journal-title":"Cancer Res"},{"key":"BFleu200874_CR22","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1172\/JCI116786","volume":"92","author":"M Wetzler","year":"1993","unstructured":"Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R . Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993; 92: 1925\u20131939.","journal-title":"J Clin Invest"},{"key":"BFleu200874_CR23","first-page":"5995","volume":"62","author":"C Ricci","year":"2002","unstructured":"Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line. Cancer Res 2002; 62: 5995\u20135998.","journal-title":"Cancer Res"},{"key":"BFleu200874_CR24","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1182\/blood.V97.11.3491","volume":"97","author":"M Deng","year":"2001","unstructured":"Deng M, Daley GQ . Expression of interferon consensus sequence binding protein induces potent immunity against BCR\/ABL-induced leukemia. Blood 2001; 97: 3491\u20133497.","journal-title":"Blood"},{"key":"BFleu200874_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399\u2013401.","journal-title":"Science"},{"key":"BFleu200874_CR26","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","volume":"66","author":"AK Samanta","year":"2006","unstructured":"Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB . Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006; 66: 6468\u20136472.","journal-title":"Cancer Res"},{"key":"BFleu200874_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1124\/mol.61.1.222","volume":"61","author":"Y Zhou","year":"2002","unstructured":"Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P . Action of (E)-2\u2032-deoxy-2\u2032-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol 2002; 61: 222\u2013229.","journal-title":"Mol Pharmacol"},{"key":"BFleu200874_CR28","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1182\/blood-2002-08-2512","volume":"101","author":"Y Zhou","year":"2003","unstructured":"Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P . Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101: 4098\u20134104.","journal-title":"Blood"},{"key":"BFleu200874_CR29","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/sj.leu.2403968","volume":"19","author":"RH Xu","year":"2005","unstructured":"Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P . Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 2005; 19: 2153\u20132158.","journal-title":"Leukemia"},{"key":"BFleu200874_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1006\/abio.2001.5030","volume":"291","author":"L Liebes","year":"2001","unstructured":"Liebes L, Conaway CC, Hochster H, Mendoza S, Hecht SS, Crowell J et al. High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. Anal Biochem 2001; 291: 279\u2013289.","journal-title":"Anal Biochem"},{"key":"BFleu200874_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejphar.2005.06.021","volume":"518","author":"SJ Wu","year":"2005","unstructured":"Wu SJ, Ng LT, Lin CC . Effects of antioxidants and caspase-3 inhibitor on the phenylethyl isothiocyanate-induced apoptotic signaling pathways in human PLC\/PRF\/5 cells. Eur J Pharmacol 2005; 518: 96\u2013106.","journal-title":"Eur J Pharmacol"},{"key":"BFleu200874_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.bcp.2004.04.010","volume":"68","author":"JH Bang","year":"2004","unstructured":"Bang JH, Han ES, Lim I, Lee CS . Differential response of MG132 cytotoxicity against small cell lung cancer cells to changes in cellular GSH contents. Biochem Pharmacol 2004; 68: 659\u2013666.","journal-title":"Biochem Pharmacol"},{"key":"BFleu200874_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1046\/j.1365-2141.2002.03468.x","volume":"117","author":"AM Di Bacco","year":"2002","unstructured":"Di Bacco AM, Cotter TG . p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases. Br J Haematol 2002; 117: 588\u2013597.","journal-title":"Br J Haematol"},{"key":"BFleu200874_CR34","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1128\/MCB.23.8.2790-2799.2003","volume":"23","author":"D Barila","year":"2003","unstructured":"Barila D, Rufini A, Condo I, Ventura N, Dorey K, Superti-Furga G et al. Caspase-dependent cleavage of c-Abl contributes to apoptosis. Mol Cell Biol 2003; 23: 2790\u20132799.","journal-title":"Mol Cell Biol"},{"key":"BFleu200874_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.cdd.4401336","volume":"11","author":"N Machuy","year":"2004","unstructured":"Machuy N, Rajalingam K, Rudel T . Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis. Cell Death Differ 2004; 11: 290\u2013300.","journal-title":"Cell Death Differ"},{"key":"BFleu200874_CR36","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-06-1863","volume":"67","author":"K Podar","year":"2007","unstructured":"Podar K, Raab MS, Tonon G, Sattler M, Barila D, Zhang J et al. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res 2007; 67: 1680\u20131688.","journal-title":"Cancer Res"},{"key":"BFleu200874_CR37","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1038\/sj.onc.1209477","volume":"25","author":"X Ling","year":"2006","unstructured":"Ling X, Wang Y, Dietrich MF, Andreeff M, Arlinghaus RB . Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene 2006; 25: 4483\u20134490.","journal-title":"Oncogene"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu200874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu200874","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu200874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:23:15Z","timestamp":1648729395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu200874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,3]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["BFleu200874"],"URL":"https:\/\/doi.org\/10.1038\/leu.2008.74","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,3]]},"assertion":[{"value":"22 November 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}